ERAS Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 3.95%, SMA50 21.94%, SMA200 87.66%). The stock’s 14-day RSI is 59.64 (neutral), while the ATR of 0.23 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -6.84% below its high and over 250.5% above its low. Average 10-day trading volume of 1.72 million shares is below the 3-month average of 2.10 million, indicating normal recent market interest.

Erasca, Inc. has 283.67 million shares outstanding. The public float is 167.46 million shares, elevated short interest at 7.64% of float. This equals 19.06 million shares. The short ratio is 20.77 days. Institutional investors hold 92.76% of the float. Insiders own 11.68%. Lim Jonathan E holds 12.90 million shares, Chen Bihua has 10.81 million shares and Casdin Alexander W. has 573.97 thousand shares.

Erasca, Inc. generated EPS of -$0.45 over the past year. Five-year average earnings growth is -46.86%. Wall Street analysts project EPS growth of 11.89% annually over the next five years. The latest quarter delivered EPS of -$0.11. The next quarter is forecast at -$0.11. Next year's EPS is expected at -$14.35. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 5 Buy ratings, 1 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $6.00 to $1.00. The high target offers 69.49% upside. The low target suggests -71.75% downside. The mean target is $4.00. This offers 12.99% upside. Erasca, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by 0.0%. The prior quarter beat by -1.9%. Over the last six quarters, Apple has recorded several small beats. These include -35.29% in November 12, 2024.

Erasca, Inc. (NASDAQ:ERAS) closed at $3.54 USD, gaining $0.08 (2.31%) from the previous close of $3.46. The stock is currently mid-range between its 52-week high and low $1.01 and $3.80. With a market capitalization of about $1.00 billion, Erasca, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.17). Key stats such as the average daily volume over the past year has been around 2.08 million shares, in line with its 52-week average. Headquartered in San Diego, CA, Erasca, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jonathan E. Lim, the company employs approximately 103 people and listed since July 16, 2021. Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

Erasca, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.07. This means the shares are trading above this model’s fair value.

Erasca, Inc. trades at a P/E ratio of -7.69, slightly below the S&P 500 average, with a price-to-sales ratio of 235.3 and a price-to-book ratio of 2.65 suggesting the stock is closer to book value. The P/FCF stands at -9.95, also below market averages.

Our AI price prediction model suggests that Erasca, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.8%, with price expected at $3.71 by January 13, 2026, within a range of $3.57 to $3.84 3-Month Outlook: Projected fall of -14.97%, reaching $3.01 by March 27, 2026, with a range of $2.93 to $3.08. 1-Year Outlook: Projected gain of 748.02%, with price at $30.02 by December 30, 2026, within a range of $25.25 to $38.63.

Erasca, Inc. (NASDAQ:ERAS) shares are up 41.04% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Erasca, Inc. trading at a premium to the broader market with a P/E of -7.69. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $6.41, suggesting 81.07% upside. Our AI forecast model points to short-term strength (4.8% over two weeks), a medium-term fall (-14.97% over three months), and a longer-term gain (748.02% over one year), with expected trading ranges indicating moderate volatility.